These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32282176)

  • 1. Schizophrenia: opportunities to improve outcomes and reduce economic burden through managed care.
    Wander C
    Am J Manag Care; 2020 Mar; 26(3 Suppl):S62-S68. PubMed ID: 32282176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia: a managed care perspective.
    Liu J
    Am J Manag Care; 2014 Jun; 20(8 Suppl):S174-83. PubMed ID: 25180707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost of schizophrenia.
    Wasylenki DA
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S65-9. PubMed ID: 7874667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
    Offord S; Lin J; Mirski D; Wong B
    Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of relapse in schizophrenia.
    Weiden PJ; Olfson M
    Schizophr Bull; 1995; 21(3):419-29. PubMed ID: 7481573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs).
    Brugnoli R; Rapinesi C; Kotzalidis GD; Marcellusi A; Mennini FS; De Filippis S; Carrus D; Ballerini A; Francomano A; Ducci G; Del Casale A; Girardi P
    Riv Psichiatr; 2016; 51(2):47-59. PubMed ID: 27183509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
    Phanthunane P; Whiteford H; Vos T; Bertram M
    J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.
    Pilon D; Muser E; Lefebvre P; Kamstra R; Emond B; Joshi K
    BMC Psychiatry; 2017 Jun; 17(1):207. PubMed ID: 28576133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annual health outcomes and treatment costs for schizophrenia populations.
    Mauskopf JA; David K; Grainger DL; Gibson PJ
    J Clin Psychiatry; 1999; 60 Suppl 19():14-9; discussion 20-2. PubMed ID: 10507276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
    Edwards NC; Rupnow MF; Pashos CL; Botteman MF; Diamond RJ
    Pharmacoeconomics; 2005; 23(3):299-314. PubMed ID: 15836010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic burden of schizophrenia in the United States in 2002.
    Wu EQ; Birnbaum HG; Shi L; Ball DE; Kessler RC; Moulis M; Aggarwal J
    J Clin Psychiatry; 2005 Sep; 66(9):1122-9. PubMed ID: 16187769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managed care considerations. Optimal pharmacotherapy of schizophrenia.
    Muller R
    Manag Care; 2014 Apr; 23(4 Suppl 1):4. PubMed ID: 25029780
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.
    Haycox A
    Pharmacoeconomics; 2005; 23 Suppl 1():3-16. PubMed ID: 16416758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic and societal burden of Alzheimer disease: managed care considerations.
    Skaria AP
    Am J Manag Care; 2022 Sep; 28(10 Suppl):S188-S196. PubMed ID: 36197132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.